Rate of ROP doubles in Denmark

Article

A Danish study published in the January issue of Pediatrics has found that the incidence of retinopathy of prematurity (ROP) treatment in Denmark has more than doubled during the past five years.

A Danish study published in the January issue of Pediatrics has found that the incidence of retinopathy of prematurity (ROP) treatment in Denmark has more than doubled during the past five years.

Carina Slidsborg and colleagues from Copenhagen University Hospital and the National Board of Health, Copenhagen, Denmark examined the patient charts of infants treated for ROP and the national birth registry to gather information about neonatal parameters. These parameters, along with birth in the latter half of the period (2001?2005), were analysed as risk factors for ROP. The national registry for blind and visually impaired children was accessed to obtain information about visual impairment attributable to ROP in both treated and untreated infants.

The study included 5,467 Danish preterm infants, 2,616 born between 1996 and 2000 and 2,851 born between 2001 and 2005. The incidence of treated ROP cases increased significantly from 1.3% during the 1996-2000 period to 3.5% during the 2001-2005 period. Significant risk factors for ROP treatment included low gestational age, small for gestational age, male gender and multiple birth. Of the study population, 0.6% were registered as visually impaired due to ROP within two years after birth. Of all the early-detected, visually impaired children, 16% had not been treated for ROP and were considered screening failures.

The incidence of ROP has more than doubled over the past five years in Denmark and, according to the authors, this increase cannot be fully explained by increased survival rates or by changes in the investigational neonatal risk factors.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.